OnKure Therapeutics, Inc. (OKUR)

Market Cap	36.72M -49.5%
Revenue (ttm)	n/a
Net Income	-63.46M
EPS	-4.76
Shares Out	13.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	143,409
Open	2.680
Previous Close	2.660
Day's Range	2.620 - 2.900
52-Week Range	1.700 - 5.600
Beta	n/a
Analysts	Strong Buy
Price Target	32.00 (+1,080.81%)
Earnings Date	Mar 10, 2026

About OKUR

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 46
• Stock Exchange: NASDAQ
• Ticker Symbol: OKUR
• Website: https://onkuretherapeutics.com

Analyst Summary

According to 2 analysts, the average rating for OKUR stock is "Strong Buy." The 12-month stock price target is $32.0, which is an increase of 1,080.81% from the latest price.

Price Target

$32.0

(1,080.81% upside)

Analyst Consensus: Strong Buy